The Lancet Oncology· Sagar Lonial, Meletios A Dimopoulos, Maria Gavriatopoulou, Kihyun Kim, Chang-Ki Min, Albert Oriol, Catarina Campos Costa Moreira, Hang Quach, Lugui Qiu, Zhongjun Xia, Fredrik Schjesvold, Ignacio Casas-Avilés, Yan Xu, Vania Hungria, Güldane C Seval, Baijun Fang, Charalampia Kyriakou, Henry Miles Prince, Junling Zhuang, Hsin-Chen Lin, María-Victoria Mateos, Ivan Špička, Angelo Maiolino, Filiz Vural, Supratik Basu, Dominik Dytfeld, Chengcheng Fu, Phoebe Joy Ho, Nisha Joseph, Michael Low, Ludek Pour, Saulius Girnius, Jesús G Berdeja, Paula Rodríguez Otero, Yiming Cheng, Michael Amatangelo, Sarah Hersey, Christian Kazanecki, Marija Bosilkovska Weisskopf, Margee J Kyada, Patricia C Abad, Shuyu Chu, Juliane Morando, Paulo Maciag, Paul G Richardson, Niels WCJ van de Donk, EXCALIBER-RRMM Investigators·· 2026-09-25AI 评分56
伊伯多米德联合达克珠单抗与地塞米松对比达克珠单抗、硼替佐米与地塞米松治疗复发性/难治性多发性骨髓瘤的III期随机对照试验(EXCALIBER-RRMM)
[Articles] Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
AI 导读
伊伯多米德联合达克珠单抗与地塞米松对比达克珠单抗、硼替佐米与地塞米松治疗复发性/难治性多发性骨髓瘤的III期随机对照试验(EXCALIBER-RRMM)显示,联合方案显著提高MRD阴性完全缓解率。研究由The Lancet Oncology发布,主要结果为Iberdomide+方案在疗效和安全性上具有优势,支持其作为治疗新选项。
来源:The Lancet Oncology · thelancet.com